Icon

PRADAXA (nda022512)- (EQ 75MG BASE,EQ 150MG BASE,EQ 110MG BASE)

DABIGATRAN ETEXILATE MESYLATE BOEHRINGER INGELHEIM
EQ 75MG BASE,EQ 150MG BASE,EQ 110MG BASE
Yes No
2031-Jul-20 2015-Oct-19
None None
None No
PRADAXA Capsules is a direct thrombin inhibitor indicated: • To reduce the risk of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation • For the treatment of deep venous thrombosis (DVT) and pulmonary embolism (PE) in adult patients who have been treated with a parenteral anticoagulant for 5-10 days • To reduce the risk of recurrence of DVT and PE in adult patients who have been previously treated • For the prophylaxis of DVT and PE in adult patients who have undergone hip replacement surgery • For the treatment of venous thromboembolic events (VTE) in pediatric patients 8 to less than 18 years of age who have been treated with a parenteral anticoagulant for at least 5 days • To reduce the risk of recurrence of VTE in pediatric patients 8 to less than 18 years of age who have been previously treated
5 6 5
Total Other Developers 20
Drugs with Suitability No
EQ 75MG BASE ** ** Down - 5
EQ 150MG BASE ** ** Down - 5
EQ 110MG BASE ** ** - - -
NDA Sales Available Total Generic Sales Available
Yes 2
ANDA No Generic Co Manufacturer Name Operations Manufacturer Address Country
****** ****** **** *** *** ****** **** ******* *********** **** ***, **** **. **-***, ****-**, ***, **********, *********, ********* ******, ***** (***) ***
****** ****** **** *** *** ****** *************** *** *********** *** * ********** **, ******* *****, *** **** (**) *****, ****** ****** (***) ***
****** ***** **** *** ***** ************ ******* *********** **** **. ***/*, ***, ***/*, ***/* & ***/* ******* ****** ***** *****, *******, *****, ***** & *** ******, ***** (***) ***
****** *** *** ************ ******* ******* *********** ************ ********, ****-**, ****** ***. ****& **** ** ****, ********* (*******), ********* (******), ********** ********, ********* ******, ***** (***) ***
****** ****** ****** ***. *********** *** ****** *****, *******, ******* *** ***, ****** (***) ***
****** ****** ****** ***. *********** ** ******** ****., *********, ******* *** ***, ****** (***) ***
****** ******* ******* *************** ******* *********** *********** ********, ******* *******, *.*. *******, **** *****, ****** *****,, **********, ******* ******, ***** (***) ***

Download GenUS Drug Report


Download GenUS Detailed Report


To get detailed report Contact Us

GenUs Advanced Search




Expired
to
Expired
to


Brand Name Generic Name Strength Dosage Route of Administration Innovator ParaIV

Please contact contact@researchdelta.com to get more details.